Current aspects of valproate in bipolar disorder

Area of Science:

• Psychiatry and Pharmacology
• Neuroscience and Behavioral Science

Background:

• Lithium has been the primary treatment for bipolar disorder for over 30 years.
• Lithium's limitations include adverse effects, slow onset, drug interactions, and a narrow therapeutic index.
• Anticonvulsants, specifically carbamazepine and valproate, have emerged as alternative or adjunctive treatments.

Purpose of the Study:

• To review existing data on valproate's efficacy and limitations in treating bipolar disorder.
• To assess valproate's potential as an alternative or adjunctive therapy compared to lithium.

Main Methods:

• Review of existing controlled and open studies on valproate in psychiatric diseases, particularly bipolar disorder.
• Analysis of data regarding valproate's effectiveness in acute mania, recurrent episodes, and specific patient subtypes.

Main Results:

• Valproate is generally well-tolerated and effective in bipolar disorder, with a rapid onset of action in acute mania.
• Open studies suggest valproate reduces the frequency and intensity of recurrent manic and depressive episodes.
• Valproate demonstrates specific efficacy in subtypes such as rapid cycling, mixed mania, and comorbid conditions.

Conclusions:

• Valproate is a promising alternative or adjunctive treatment for bipolar disorder, especially for patients unresponsive to lithium or with complex presentations.
• Its efficacy in acute mania and specific subtypes warrants further investigation.
• Additional controlled studies are necessary to establish clear treatment guidelines for valproate in bipolar disorder.